Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277 - 300; http://dx.doi.org/10.3322/caac.20073; PMID: 20610543
   PubMed Web of Science ®Google Scholar
• Wong K-K, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010; 20:87 - 90; http://dx.doi.org/10.1016/j.gde.2009.11.002; PMID: 20006486
   PubMed Web of Science ®Google Scholar
• Madrid LV, Mayo MW, Reuther JY, Baldwin AS Jr.. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 2001; 276:18934 - 40; http://dx.doi.org/10.1074/jbc.M101103200; PMID: 11259436
   PubMed Web of Science ®Google Scholar
• Sizemore N, Leung S, Stark GR. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 1999; 19:4798 - 805; PMID: 10373529
   PubMed Web of Science ®Google Scholar
• Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 1997; 14:3059 - 66; http://dx.doi.org/10.1038/sj.onc.1201154; PMID: 9223669
   PubMed Web of Science ®Google Scholar
• Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998; 16:3215 - 8; http://dx.doi.org/10.1038/sj.onc.1201855; PMID: 9671402
   PubMed Web of Science ®Google Scholar
• Aveyard JS, Skilleter A, Habuchi T, Knowles MA. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999; 80:904 - 8; http://dx.doi.org/10.1038/sj.bjc.6690439; PMID: 10360673
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489 - 501; http://dx.doi.org/10.1038/nrc839; PMID: 12094235
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341 - 54; http://dx.doi.org/10.1038/nrc1609; PMID: 15864276
   PubMed Web of Science ®Google Scholar
• López-Knowles E, Hernández S, Malats N, Kogevinas M, Lloreta J, Carrato A, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006; 66:7401 - 4; http://dx.doi.org/10.1158/0008-5472.CAN-06-1182; PMID: 16885334
   PubMed Web of Science ®Google Scholar
• Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009; 15:6008 - 17; http://dx.doi.org/10.1158/1078-0432.CCR-09-0898; PMID: 19789314
   PubMed Web of Science ®Google Scholar
• Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF, Knowles MA. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 2010; 29:150 - 5; http://dx.doi.org/10.1038/onc.2009.315; PMID: 19802009
   PubMed Web of Science ®Google Scholar
• Wu X-R. Biology of urothelial tumorigenesis: insights from genetically engineered mice. Cancer Metastasis Rev 2009; 28:281 - 90; http://dx.doi.org/10.1007/s10555-009-9189-4; PMID: 20012171
   PubMed Web of Science ®Google Scholar
• Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009; 23:675 - 80; http://dx.doi.org/10.1101/gad.1772909; PMID: 19261747
   PubMed Web of Science ®Google Scholar
• Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 2010; 10:241 - 53; http://dx.doi.org/10.1038/nrc2820; PMID: 20300105
   PubMed Web of Science ®Google Scholar
• Knowles MA, Platt FM, Ross RL, Hurst CD. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 2009; 28:305 - 16; http://dx.doi.org/10.1007/s10555-009-9198-3; PMID: 20013032
   PubMed Web of Science ®Google Scholar
• Kassouf W, Dinney CPN, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res 2005; 65:10524 - 35; http://dx.doi.org/10.1158/0008-5472.CAN-05-1536; PMID: 16288045
   PubMed Web of Science ®Google Scholar
• Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CPN, et al. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res 2007; 67:1430 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-06-1224; PMID: 17308080
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926 - 45; http://dx.doi.org/10.1101/gad.1212704; PMID: 15314020
   PubMed Web of Science ®Google Scholar
• Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785 - 9; http://dx.doi.org/10.1038/378785a0; PMID: 8524413
   PubMed Web of Science ®Google Scholar
• Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12:3499 - 511; http://dx.doi.org/10.1101/gad.12.22.3499; PMID: 9832503
   PubMed Web of Science ®Google Scholar
• Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, et al. Inhibitor hijacking of Akt activation. Nat Chem Biol 2009; 5:484 - 93; http://dx.doi.org/10.1038/nchembio.183; PMID: 19465931
   PubMed Web of Science ®Google Scholar
• Tsuruta H, Kishimoto H, Sasaki T, Horie Y, Natsui M, Shibata Y, et al. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 2006; 66:8389 - 96; http://dx.doi.org/10.1158/0008-5472.CAN-05-4627; PMID: 16951148
   PubMed Web of Science ®Google Scholar
• Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J, et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila) 2009; 2:1008 - 14; http://dx.doi.org/10.1158/1940-6207.CAPR-09-0169; PMID: 19952358
   PubMed Web of Science ®Google Scholar
• Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, et al. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int 2010; PMID: 21050361
   PubMed Web of Science ®Google Scholar
• Chiong E, Lee I-L, Dadbin A, Sabichi AL, Harris L, Urbauer D, et al. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 2011; 17:2863 - 73; http://dx.doi.org/10.1158/1078-0432.CCR-09-3202; PMID: 21415218
   PubMed Web of Science ®Google Scholar
• O’Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-05-2925; PMID: 16452206
   PubMed Web of Science ®Google Scholar
• Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008; 7:1347 - 54; http://dx.doi.org/10.1158/1535-7163.MCT-07-2408; PMID: 18566209
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274 - 93; http://dx.doi.org/10.1016/j.cell.2012.03.017; PMID: 22500797
   PubMed Web of Science ®Google Scholar
• Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 2005; 6:439 - 48; http://dx.doi.org/10.1038/nrm1660; PMID: 15928708
   PubMed Web of Science ®Google Scholar
• Kundu M, Thompson CB. Autophagy: basic principles and relevance to disease. Annu Rev Pathol 2008; 3:427 - 55; http://dx.doi.org/10.1146/annurev.pathmechdis.2.010506.091842; PMID: 18039129
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4:151 - 75; PMID: 18188003
   PubMed Web of Science ®Google Scholar
• Miled N, Yan Y, Hon W-C, Perisic O, Zvelebil M, Inbar Y, et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007; 317:239 - 42; http://dx.doi.org/10.1126/science.1135394; PMID: 17626883
   PubMed Web of Science ®Google Scholar
• Kang S, Bader AG, Zhao L, Vogt PK. Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle 2005; 4:578 - 81; http://dx.doi.org/10.4161/cc.4.4.1593; PMID: 15876869
   PubMed Web of Science ®Google Scholar
• Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004; 3:1221 - 4; http://dx.doi.org/10.4161/cc.3.10.1164; PMID: 15467468
   PubMed Web of Science ®Google Scholar
• McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009; 28:335 - 44; http://dx.doi.org/10.1007/s10555-009-9194-7; PMID: 20012924
   PubMed Web of Science ®Google Scholar
• Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009; 15:5060 - 72; http://dx.doi.org/10.1158/1078-0432.CCR-08-2245; PMID: 19671845
   PubMed Web of Science ®Google Scholar
• van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277:805 - 8; http://dx.doi.org/10.1126/science.277.5327.805; PMID: 9242607
   PubMed Web of Science ®Google Scholar
• Consortium ECTS, European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75:1305 - 15; http://dx.doi.org/10.1016/0092-8674(93)90618-Z; PMID: 8269512
   PubMed Web of Science ®Google Scholar
• Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003; 13:1259 - 68; http://dx.doi.org/10.1016/S0960-9822(03)00506-2; PMID: 12906785
   PubMed Web of Science ®Google Scholar
• Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 1993; 8:1083 - 5; PMID: 8096074
   PubMed Web of Science ®Google Scholar
• Knowles MA, Habuchi T, Kennedy W, Cuthbert-Heavens D. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 2003; 63:7652 - 6; PMID: 14633685
   PubMed Web of Science ®Google Scholar
• Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, Brown N, et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 1995; 154:1532 - 8; http://dx.doi.org/10.1016/S0022-5347(01)66923-4; PMID: 7658585
   PubMed Web of Science ®Google Scholar
• Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo W-L, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer. Cancer Res 2008; 68:6084 - 91; http://dx.doi.org/10.1158/0008-5472.CAN-07-6854; PMID: 18676830
   PubMed Web of Science ®Google Scholar
• Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011; 104:75 - 82; http://dx.doi.org/10.1038/sj.bjc.6606016; PMID: 21119661
   PubMed Web of Science ®Google Scholar